This study will investigate the efficacy and safety of OZURDEX® (dexamethasone intravitreal
implants; DEX, Allergan, Inc. Irvine, CA) as monotherapy for the treatment of non-infectious
intermediate-, posterior- or panuveitis. This is a prospective randomized controlled clinical
trial taking place at the University of Ottawa Eye Institute, Ottawa, Ontario, Canada, and
other possible centers in Canada. Consecutive consenting subjects who meet
inclusion/exclusion criteria will be selected to participate in this study. The subjects must
have either non-infectious intermediate, posterior, or panuveitis. The subjects will be
randomly chosen to be part of one of two groups; one group will receive DEX as monotherapy
and the other group will receive oral prednisone. Approximately 84 eyes (42 per arm) will
take part in study. The primary outcome will measure the proportion of eyes with a vitreous
haze score of 0 six months post initial treatment. Secondary measures will include best
corrected visual acuity (BCVA), central retinal thickness (CRT) measured by spectral-domain
optical coherence tomography (SD-OCT), time to vitreous haze resolution and time to failure
defined at number of months with DEX implant until an adjunct therapy is indicated. Baseline
measurements will be recorded within 1 month prior to treatment in both groups, with follow
up measurements collected at 0, 1, 2, 4, 6 and 12 months post-operatively.